MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Svelte Medical granted CE Mark for Slender IDS drug-eluting stent catheter

Svelte Medical granted CE Mark for Slender IDS drug-eluting stent catheter

By

Svelte MedicalSvelte Medical Systems said today it won CE Mark approval in the European Union for its Slender sirolimus-eluting coronary stent-on-a-wire integrated delivery system designed to treat coronary artery disease.

The Slender IDS is the lowest-profile drug-eluting stent on the market, according to the New Providence, N.J.-based company. Approval in the EU came based on data from the Direct I and Direct II clinical studies of the device.

“Slender IDS is an entirely new approach to coronary stenting, offering unique clinical and procedural benefits which we look forward to integrating into our practice. No reports of stent thrombosis dating back nearly 4 years to the 1st-in-man study are reassuring signals relating to safety, and product efficacy appears as good as any current generation DES. The unique attributes of this product help us in our ongoing efforts to optimize patient care,” principal investigator Dr. Stefan Verheye of Belgium’s Antwerp Cardiovascular Institute at the Middelheim Hospital said in a press release.

The device incorporates Japan’s Asahi Intecc (TYO:7747) guide wire technology, specialized balloon design and a bioresorbable drug carrier from DSM Biomedical. The Slender’s all-in-one’ fixed-wire system with combined technologies allows for “precise steering” and controlled balloon growth for performing direct stenting in high-pressure post-dilations, Svelte Medical said.

“Adding value in the modern healthcare environment requires new technologies to improve efficiency and reduce cost while enhancing patient outcomes and comfort. Slender IDS is a highly differentiated platform delivering value to all constituents involved in coronary stenting – patients, physicians, providers and payers. We are extremely pleased to achieve the CE Mark for Slender IDS and look forward to introducing it in cath labs in Europe,” CEO Jack Darby said in prepared remarks.

Svelte Medical siad it plans to commercialize the device in select European markets and will commence an investigational device exemption study to support premarket approval with the FDA in 2016.

The company said it has plans for a rapid-exchange DES system for direct stenting to be on the market in Europe in 2016.

In case you missed it

RSS From Medical Design & Outsourcing

  • Tegra Medical announces new director of sales and marketing in Europe
    Tegra Medical announced that it appointed Darren Vine as its director of sales and marketing in Europe. Franklin, Mass.-based Tegra said in a news release that Vine will report to CEO and head of SFS division medical Walter Kobler, with responsibilities including the building of the company’s presence through expansion into new markets around the… […]
  • 5 challenges Boston Scientific overcame to make single-use scopes work
    FDA wanted single-use scopes to reduce potentially deadly superbug infections. Here’s how Boston Scientific made it happen. Boston Scientific’s Exalt Model D Single-Use Duodenoscope received FDA clearance in December 2019. It was the first device of its kind to hit the medical market. Just five months earlier, the FDA urged device manufacturers to move away from re-usable duodenoscopes with… […]
  • Veranex acquires Experien Group
    Veranex announced today that it acquired Experien Group, a provider of regulatory, quality and clinical consulting services for medtech companies. Raleigh, N.C.-based Veranex, which was created as a combination of companies after Summit Partners acquired Ximedica, Quartesian and Boston Healthcare Associates in June, offers integrated product development strategies and services to medtech companies. According to… […]
  • How Olympus is using AI to find patients for its COPD device
    Olympus recently announced its SeleCT Connect program, which uses diagnostic imaging AI to automatically screen which people might benefit from its Spiration valve system. Spiration is an FDA-designated breakthrough device for treating chronic obstructive pulmonary disease (COPD) patients. SeleCT Connect — offered as part of Olympus’ SeleCT quantitative computer tomography (QCT) analysis service — is… […]
  • Catheter & Medical Design and VitalDyne Medical rebrand as VitalPath
    Catheter & Medical Design and VitalDyne Medical — makers of complex medical catheter systems — have rebranded under the name VitalPath. The move comes about five months after CMD’s March 2021 acquisition of VitalDyne. The Roseville, Minn.–based company also has a new website at vitalpath.com. VitalPath will exhibit at booth  No. 1714 at MD&M West,… […]
  • Dymax touts newest formulations for medtech wearables
    Dymax is using MD&M West in Anaheim, Calif. next week to tout its newest formulations for assembling medical device wearables. The Dymax materials are free from IBOA and TPO, are compatible with common and difficult substrates, and have passed ISO 10993-10 for sensitization and irritation, according to the Torrington, Conn.–based company. For manufacturers involved with… […]
  • What is a proportional isolation valve?
    A “proportional” isolation valve can bring the next level of control and design for engineers, especially in life science industries. Doug Paynter, Clippard When we talk about proportional valves, whether they are pneumatic or hydraulic, we typically refer to valves that vary their flow path when you apply an increasing or decreasing amount of power/current… […]
  • CoorsTek scores EU legal win in pink components trademark dispute
    The EU Trademark Court of Appeals in Paris recently upheld a Paris EU Trademark High Court decision that sided with CoorsTek against CeramTec in a trademark dispute over “pink” ceramic hip components. The Paris Court of Appeals in its June 2021 ruling upheld the cancelations of the three EU trademarks and the dismissal of CeramTec’s… […]
  • Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent
    Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform. When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation. As a practicing interventional cardiologist, West remembers… […]
  • Versapor® RC Membranes: The next generation of venting materials
    As the world leader in the design and production of membranes, filtration devices, and separation systems, Pall Corporation supplies products to nearly every industry in the world. Founded in 1946, Pall Corporation has set the standard for filtration solutions for 75 years and counting. Our customers have relied on us for their most sophisticated applications… […]
  • Tips to help bring your medical device from mind to market
    By Bret Ludwig, Ph.D. Senior Product Development Specialist, 3M Medical Materials & Technologies Great medical devices start with an idea—a spark. And from there, it might move to the back of a napkin or a notepad. But as development continues, the process can get trickier and more complex. In fact, turning an idea into a… […]